Roussel R, et al. - The effects of continuing vs discontinuing sitagliptin when initiating and intensively titrating insulin glargine were compared in this study. Patients who had inadequately controlled type 2 diabetes on metformin treatment (≥ 1500 mg/d) in combination with a dipeptidyl peptidase-4 (DPP-4) inhibitor and/or a sulphonylurea were eligible for inclusion in this study. Direct randomization of those on metformin plus sitagliptin was done; all others were switched to metformin plus sitagliptin (discontinuing other DPP-4 inhibitors and sulphonylureas) and stabilized during a run-in period. Treatment was performed on a total of 743 participants (mean glycated hemoglobin [HbA1c] 72.6 mmol/mol [8.8%]; disease duration 10.8 years). Researchers noted a clinically meaningful greater reduction in HbA1c with continuation of sitagliptin on initiating insulin glargine therapy compared with discontinuation, without an increase in hypoglycemia.